m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial.
Bruce W. Dana(Unknown), Richard I. Fisher(University of Rochester), Charles A. Coltman(Wilford Hall Ambulatory Surgical Center), Thomas P. Miller(Queen Elizabeth University Hospital), Katurah Hartley(SWOG Cancer Research Network), Robert J. Hartsock(Allegheny General Hospital), S P Balcerzak, Steve Dahlberg(Georgetown University), Juan Carden(SWOG Cancer Research Network)
Cited by 53
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Oncogenically active MYD88 mutations in human lymphoma
|Nature|2010|1.5k
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
|New England Journal of Medicine|2004|1.4k